Laser-assisted Photoablation of Human Pluripotent Stem Cells from Differentiating Cultures
Overview
Authors
Affiliations
Due to their pluripotency and their self-renewal capacity, human pluripotent stem cells (hPSC) provide fascinating perspectives for biomedical applications. In the long term, hPSC-derived tissue-specific cells will constitute an important source for cell replacement therapies in non-regenerative organs. These therapeutic approaches, however, will critically depend on the purity of the in vitro differentiated cell populations. In particular, remaining undifferentiated hPSC in a transplant can induce teratoma formation. In order to address this challenge, we have developed a laser-based method for the ablation of hPSC from differentiating cell cultures. Specific antibodies were directed against the hPSC surface markers tumor related antigen (Tra)-1-60 and Tra-1-81. These antibodies, in turn, were targeted with nanogold particles. Subsequent laser exposure resulted in a 98,9 +/- 0,9% elimination of hPSCs within undifferentiated cell cultures. In order to study potential side effects of laser ablation on cells negative for Tra-1-60 and Tra-1-81, hPSC were mixed with GFP-positive hPSC-derived neural precursors (hESCNP) prior to ablation. These studies showed efficient elimination of hPSC while co-treated hESCNP maintained their normal proliferation and differentiation potential. In vivo transplantation of treated and untreated mixed hPSC/hESCNP cultures revealed that laser ablation can dramatically reduce the risk of teratoma formation. Laser-assisted photothermolysis thus represents a novel contact-free method for the efficient elimination of hPSC from in vitro differentiated hPSC-derived somatic cell populations.
Strategies to Improve the Safety of iPSC-Derived β Cells for β Cell Replacement in Diabetes.
Pellegrini S, Zamarian V, Sordi V Transpl Int. 2022; 35:10575.
PMID: 36090777 PMC: 9448870. DOI: 10.3389/ti.2022.10575.
Prevention of tumor risk associated with the reprogramming of human pluripotent stem cells.
Wuputra K, Ku C, Wu D, Lin Y, Saito S, Yokoyama K J Exp Clin Cancer Res. 2020; 39(1):100.
PMID: 32493501 PMC: 7268627. DOI: 10.1186/s13046-020-01584-0.
Yao C, Rudnitzki F, Huttmann G, Zhang Z, Rahmanzadeh R Int J Nanomedicine. 2017; 12:5659-5672.
PMID: 28848345 PMC: 5557627. DOI: 10.2147/IJN.S140620.
Martinez-Cerdeno V, Barrilleaux B, McDonough A, Ariza J, Yuen B, Somanath P Stem Cells Dev. 2017; 26(19):1409-1423.
PMID: 28693365 PMC: 5647528. DOI: 10.1089/scd.2017.0059.
Technical approaches to induce selective cell death of pluripotent stem cells.
Jeong H, Cho S, Lee M, Cha H Cell Mol Life Sci. 2017; 74(14):2601-2611.
PMID: 28246701 PMC: 11107638. DOI: 10.1007/s00018-017-2486-0.